Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
Ontology highlight
ABSTRACT: Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the appearance of disease phenotypes or in advanced stages of disease in the YAC128 mouse model of HD. In the early treatment cohort, animals received 0, 10, or 30 mg/kg pridopidine for a period of 10.5 months. In the late treatment cohort, animals were treated for 8 weeks with 0 mg/kg or an escalating dose of pridopidine (10 to 30 mg/kg over 3 weeks). Early treatment improved motor coordination and reduced anxiety- and depressive-like phenotypes in YAC128 mice, but it did not rescue striatal and corpus callosum atrophy. Late treatment, conversely, only improved depressive-like
SUBMITTER: Garcia-Miralles M
PROVIDER: S-EPMC5752291 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA